Why Did SoundHound AI Stock Go Up?
SoundHound AI (NASDAQ:SOUN) has moved higher in recent days, breaking…
Sell
47
RLMD Quote, Financials, Valuation and Earnings
Last price:
$3.91
Seasonality move
:
21.39%
Day range:
$3.78 - $4.07
52-week range:
$0.24 - $5.12
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
30.68x
Volume:
434.8K
Avg. volume:
770.7K
1-year change:
915.65%
Market cap:
$290.4M
Revenue:
--
EPS (TTM):
-$1.80
Analysts' Opinion
-
Consensus RatingRelmada Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.67, Relmada Therapeutics, Inc. has an estimated upside of 68.35% from its current price of $3.96.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $3.96.
Fair Value
-
According to the consensus of 3 analysts, Relmada Therapeutics, Inc. has 68.35% upside to fair value with a price target of $6.67 per share.
RLMD vs. S&P 500
-
Over the past 5 trading days, Relmada Therapeutics, Inc. has overperformed the S&P 500 by 3.52% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Relmada Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Relmada Therapeutics, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Relmada Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Relmada Therapeutics, Inc. has grown year-over-year earnings for 14 quarters straight. In the most recent quarter Relmada Therapeutics, Inc. reported earnings per share of -$0.30.
Enterprise value:
276.5M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.20x
EV / Free cash flow:
-6.91x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-170.01%
Net Income Margin (TTM):
--
Return On Equity:
-214.4%
Return On Invested Capital:
-214.4%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$115.6M | -$91.6M | -$57.8M | -$23M | -$10.3M | |
| EBITDA | -$115.6M | -$91.6M | -$57.8M | -$23M | -$10.3M | |
| Diluted EPS | -$3.71 | -$2.87 | -$1.80 | -$0.72 | -$0.30 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $90.9M | $187.1M | $109.1M | $55.7M | $14.9M | |
| Total Assets | $90.9M | $187.1M | $109.1M | $55.7M | $14.9M | |
| Current Liabilities | $18.2M | $20.8M | $8.4M | $8.1M | $5.2M | |
| Total Liabilities | $18.2M | $20.8M | $8.4M | $8.1M | $5.4M | |
| Total Equity | $72.7M | $166.3M | $100.7M | $47.6M | $9.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$77.3M | -$53.2M | -$40M | -$16.7M | -$6.7M | |
| Cash From Investing | $41.1M | $48M | $40.1M | $16.1M | $6.8M | |
| Cash From Financing | $409.9K | $33.7K | -$245.5K | -$89.6K | -- | |
| Free Cash Flow | -$77.3M | -$53.2M | -$40M | -$16.7M | -$6.7M | |
RLMD
Sector
Market Cap
$290.4M
$26M
Price % of 52-Week High
77.34%
51.81%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.66%
1-Year Price Total Return
915.65%
-18.29%
Beta (5-Year)
0.772
0.485
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.91
200-day SMA
Buy
Level
$1.80
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$4.23
Relative Strength Index (RSI14)
Sell
Level
46.80
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-73.5695
50-day SMA
Sell
Level
$4.13
MACD (12, 26)
Buy
Level
0.51
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-23.7806)
Sell
CA Score
(Annual)
Level (-4.1661)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (16.1487)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.
Stock Forecast FAQ
In the current month, RLMD has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The RLMD average analyst price target in the past 3 months is $6.67.
-
Where Will Relmada Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Relmada Therapeutics, Inc. share price will rise to $6.67 per share over the next 12 months.
-
What Do Analysts Say About Relmada Therapeutics, Inc.?
Analysts are divided on their view about Relmada Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Relmada Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is Relmada Therapeutics, Inc.'s Price Target?
The price target for Relmada Therapeutics, Inc. over the next 1-year time period is forecast to be $6.67 according to 3 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is RLMD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Relmada Therapeutics, Inc. is a Buy. 2 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RLMD?
You can purchase shares of Relmada Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Relmada Therapeutics, Inc. shares.
-
What Is The Relmada Therapeutics, Inc. Share Price Today?
Relmada Therapeutics, Inc. was last trading at $3.91 per share. This represents the most recent stock quote for Relmada Therapeutics, Inc.. Yesterday, Relmada Therapeutics, Inc. closed at $3.96 per share.
-
How To Buy Relmada Therapeutics, Inc. Stock Online?
In order to purchase Relmada Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get RLMD Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
RLMD
Sector
P/E ratio
--
23.85x
PEG ratio
-0.20x
-0.01x
P/B ratio
30.68x
1.83x
Price / LTM sales
--
1.56x
Growth Metrics
RLMD
Sector
Revenue growth
--
4.18%
Earnings growth
57.78%
9.66%
Revenue (5-year growth)
--
6.28%
Earnings forecast
--
-$0.18
Profitability
RLMD
Sector
Profitability FY 2024
--
$3.1M
Return on invested capital
-214.4%
-32.89%
Return on assets
-170.01%
-29.56%
Return on equity
-214.4%
-38.66%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
26
Estimated Next Earnings Date
Feb
12
Balance Sheet
RLMD
Sector
Total cash
$13.9M
$25.2M
Short term investments
$41.1M
$25.1M
Total assets
$45.8M
$73M
Long term debt
--
$3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Goldman Sachs Going to Go Up?
Shares of financial giant Goldman Sachs (NYSE:GS) have soared by…
How High Will MSTR Stock Go?
After several months of pressure, shares of Bitcoin treasury Strategy…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
69
INTC alert for Jan 23
Intel Corp. [INTC] is down 17.01% over the past day.
Buy
70
BNR alert for Jan 24
Burning Rock Biotech Ltd. [BNR] is down 12.81% over the past day.
Buy
80
MTRN alert for Jan 23
Materion Corp. [MTRN] is down 9.13% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
